Introduction

This page provides a comprehensive analysis of the known insider trading history of Michael Narachi. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Michael Narachi has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:RARE / Ultragenyx Pharmaceutical Inc. Director 32,690
US:OREX / Orexigen Therapeutics, Inc. CEO & President, Director 252,000
US:CLDN / Celladon Corp Director 50,000
US:00163UAA4 / AMAG Pharmaceuticals, Inc. 2.5% Bond Due 2/15/2019 Director 7,600
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Michael Narachi. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Trading History

This table shows the complete list of insider trades made by Michael Narachi as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-05-19 2025-05-15 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 5,740 32,690 21.30
2024-06-20 2024-06-18 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 5,345 26,950 24.74
2023-06-09 2023-06-07 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 3,860 21,605 21.75
2022-06-28 2022-06-24 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 3,300 17,745 22.85
2021-06-28 2021-06-24 4 RARE Ultragenyx Pharmaceutical Inc.
Stock Option (Right to Buy)
A - Award 4,125 4,125
2021-06-28 2021-06-24 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 2,145 14,445 17.44
2020-06-30 2020-06-26 4 RARE Ultragenyx Pharmaceutical Inc.
Stock Option (Right to Buy)
A - Award 4,250 4,250
2020-06-30 2020-06-26 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 2,550 12,300 26.15
2019-06-13 2019-06-11 4 RARE Ultragenyx Pharmaceutical Inc.
Stock Option (Right to Buy)
A - Award 5,000 5,000
2019-06-13 2019-06-11 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 3,000 9,750 44.44
2018-06-20 2018-06-19 4 RARE Ultragenyx Pharmaceutical Inc.
Stock Option (Right to Buy)
A - Award 5,000 5,000
2018-06-20 2018-06-19 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 3,000 6,750 80.00
2017-10-17 2017-10-13 4 OREX Orexigen Therapeutics, Inc.
Restricted Stock Unit (RSU)
A - Award 252,000 252,000
2017-06-22 2017-06-22 4 RARE Ultragenyx Pharmaceutical Inc.
Employee Stock Option (Right to Buy)
A - Award 3,750 3,750
2017-06-22 2017-06-22 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 1,875 3,750 100.00
2017-06-02 2017-05-31 4 OREX Orexigen Therapeutics, Inc.
Common Stock
A - Award 626 8,356 8.10 1.55 970 12,952
2017-02-07 2017-02-03 4 OREX Orexigen Therapeutics, Inc.
Stock Option
A - Award 157,500 157,500
2017-02-07 2017-02-03 4 OREX Orexigen Therapeutics, Inc.
Stock Option
A - Award 315,000 315,000
2016-12-02 2016-11-30 4 OREX Orexigen Therapeutics, Inc.
Common Stock
A - Award 802 6,312 14.56 1.67 1,339 10,541
2016-07-14 2016-07-12 4 OREX Orexigen Therapeutics, Inc.
Stock Option
A - Award 63,000 63,000
2016-07-14 2016-07-12 4 OREX Orexigen Therapeutics, Inc.
Stock Option
A - Award 315,000 315,000
2016-07-14 2016-07-12 4 OREX Orexigen Therapeutics, Inc.
Stock Option
A - Award 105,000 105,000
2016-07-14 2016-07-12 4 OREX Orexigen Therapeutics, Inc.
Stock Option
A - Award 525,000 525,000
2016-06-14 2016-06-09 4 RARE Ultragenyx Pharmaceutical Inc.
Employee Stock Option (Right to Buy)
A - Award 3,750 3,750
2016-06-14 2016-06-09 4 RARE Ultragenyx Pharmaceutical Inc.
Common Stock
A - Award 1,875 1,875
2016-06-02 2016-05-31 4 OREX Orexigen Therapeutics, Inc.
Common Stock
A - Award 8,777 69,285 14.51 0.34 2,984 23,557
2016-02-04 2016-02-02 4 OREX Orexigen Therapeutics, Inc.
Performance Stock Units
A - Award 800,000 800,000
2016-02-04 2016-02-02 4 OREX Orexigen Therapeutics, Inc.
Stock Option (right to buy)
A - Award 700,000 700,000
2016-02-04 2015-11-30 4 OREX Orexigen Therapeutics, Inc.
Common Stock
A - Award 1,761 60,508 3.00 2.03 3,575 122,831
2016-02-04 2015-05-29 4 OREX Orexigen Therapeutics, Inc.
Common Stock
A - Award 721 58,747 1.24 4.17 3,007 244,975
2015-06-22 2015-06-18 4 RARE Ultragenyx Pharmaceutical Inc.
Stock Option (Right to Buy)
A - Award 7,500 7,500
2015-06-05 2015-06-04 4 CLDN Celladon Corp
Stock option (right to buy)
A - Award 10,000 50,000 25.00
2015-02-24 2015-02-20 4 RARE Ultragenyx Pharmaceutical Inc.
Stock Option (Right to Buy)
A - Award 17,500 17,500
2015-02-05 2015-02-03 4 OREX Orexigen Therapeutics, Inc.
Stock Option (right to buy)
A - Award 635,150 635,150
2014-09-15 2014-09-15 4 OREX Orexigen Therapeutics, Inc.
Common Stock
P - Purchase 50,000 58,026 622.98 4.78 239,100 277,480
2014-05-21 2014-05-20 4 CLDN Celladon Corp
Stock option (right to buy)
A - Award 10,000 10,000
2014-02-11 2014-02-07 4 OREX Orexigen Therapeutics, Inc.
Stock Option (right to buy)
A - Award 673,500 673,500
2014-02-11 2013-11-29 4 OREX Orexigen Therapeutics, Inc.
Common Stock
A - Award 3,980 3,980 5.34 21,253 21,253
2014-02-06 2014-02-04 4 CLDN Celladon Corp
Common Stock
P - Purchase 62,500 62,500 8.00 500,000 500,000
2013-05-24 2013-05-23 4 AMAG AMAG PHARMACEUTICALS INC.
Stock Option (Right to Buy)
A - Award 7,600 7,600
2013-05-24 2013-05-23 4 AMAG AMAG PHARMACEUTICALS INC.
Common Stock
A - Award 3,800 23,900 18.91
2013-02-19 2013-02-15 4 OREX Orexigen Therapeutics, Inc.
Stock Option (right to buy)
A - Award 555,000 555,000
2012-07-19 2012-07-17 4 OREX Orexigen Therapeutics, Inc.
Stock Option (right to buy)
M - Exercise -25,762 1,774,238 -1.43
2012-07-19 2012-07-17 4 OREX Orexigen Therapeutics, Inc.
Stock Option (right to buy)
M - Exercise -124,238 1,761,562 -6.59
2012-07-19 2012-07-17 4 OREX Orexigen Therapeutics, Inc.
Common Stock
S - Sale X -25,762 0 -100.00 7.66 -197,337
2012-07-19 2012-07-17 4 OREX Orexigen Therapeutics, Inc.
Common Stock
M - Exercise X 25,762 25,762 1.70 43,795 43,795
2012-07-19 2012-07-17 4 OREX Orexigen Therapeutics, Inc.
Common Stock
S - Sale X -124,238 0 -100.00 7.66 -951,663
2012-07-19 2012-07-17 4 OREX Orexigen Therapeutics, Inc.
Common Stock
M - Exercise X 124,238 124,238 1.66 206,235 206,235
2012-07-13 2012-07-13 4 OREX Orexigen Therapeutics, Inc.
Stock Option (right to buy)
M - Exercise -147,100 1,885,800 -7.24
2012-07-13 2012-07-13 4 OREX Orexigen Therapeutics, Inc.
Common Stock
S - Sale X -147,100 0 -100.00 6.70 -985,570
2012-07-13 2012-07-13 4 OREX Orexigen Therapeutics, Inc.
Common Stock
M - Exercise X 147,100 147,100 1.66 244,186 244,186
2012-07-13 2012-07-12 4 OREX Orexigen Therapeutics, Inc.
Stock Option (right to buy)
M - Exercise -2,900 2,032,900 -0.14
2012-07-13 2012-07-12 4 OREX Orexigen Therapeutics, Inc.
Common Stock
S - Sale X -2,900 0 -100.00 6.66 -19,314
2012-07-13 2012-07-12 4 OREX Orexigen Therapeutics, Inc.
Common Stock
M - Exercise X 2,900 2,900 1.66 4,814 4,814
2012-06-29 2012-06-29 4 OREX Orexigen Therapeutics, Inc.
Stock Option (right to buy)
M - Exercise -125,000 2,035,800 -5.78
2012-06-29 2012-06-29 4 OREX Orexigen Therapeutics, Inc.
Common Stock
S - Sale X -125,000 0 -100.00 6.08 -760,000
2012-06-29 2012-06-29 4 OREX Orexigen Therapeutics, Inc.
Common Stock
M - Exercise X 125,000 125,000 1.66 207,500 207,500
2012-06-29 2012-06-28 4 OREX Orexigen Therapeutics, Inc.
Stock Option (right to buy)
M - Exercise -100,000 2,160,800 -4.42
2012-06-29 2012-06-28 4 OREX Orexigen Therapeutics, Inc.
Common Stock
S - Sale X -100,000 0 -100.00 5.66 -566,000
2012-06-29 2012-06-28 4 OREX Orexigen Therapeutics, Inc.
Common Stock
M - Exercise X 100,000 100,000 1.66 166,000 166,000
2012-05-29 2012-05-25 4 AMAG AMAG PHARMACEUTICALS INC.
Common Stock
P - Purchase 5,500 7,500 275.00
2012-05-29 2012-05-24 4 AMAG AMAG PHARMACEUTICALS INC.
Common Stock
P - Purchase 2,000 2,000 13.55 27,102 27,102
2012-05-25 2012-05-23 4 AMAG AMAG PHARMACEUTICALS INC.
Restricted Stock Unit
A - Award 3,800 3,800
2012-05-25 2012-05-23 4 AMAG AMAG PHARMACEUTICALS INC.
Stock Options
A - Award 7,600 7,600
2012-01-26 2012-01-25 4 OREX Orexigen Therapeutics, Inc.
Stock Option (right to buy)
A - Award 900,000 900,000
2009-04-02 3 OREX Orexigen Therapeutics, Inc.
No securities are beneficially owned
0
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)